Task E13: Development of Interventional Agents for Antibiotic Resistance Bacteria

任务E13：抗生素耐药性细菌介入制剂的开发

• 批准号: 10933758
• 负责人: ANTHONY GALLAGHER
• 金额: $ 15.43万
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-11 至 2024-09-11
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10933758
• 关键词: Antibiotic Resistance; Area; Biological; Biological Assay; Chemistry; Communicable Diseases; Contracts; Development; Development Plans; Drug Kinetics; Evaluation; Gram-Positive Bacteria; In Vitro; Interventional Agent Development; Lead; National Institute of Allergy and Infectious Disease; Property; Safety; Services; Support Contracts; Therapeutic; Toxicology; Toxin; bacterial resistance; in vivo; lead optimization; manufacture; pathogen; pre-clinical; product development; programs; screening; therapeutic development

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.

传染病干预药物开发的非临床服务计划提供服务，以促进针对引起传染病的病原体和/或毒素的有前景的疗法的临床前产品开发。服务包括：临床前产品开发规划和评估；先导化合物的识别和开发；化学和 GMP 制造；体外和体内临床前微生物学、安全性、毒理学和药代动力学。